GSK plc (LON:GSK)
1,931.50
-8.50 (-0.44%)
Jul 31, 2026, 4:54 PM GMT
GSK plc Revenue
GSK plc had revenue of 8.41B GBP in the quarter ending June 30, 2026, with 5.30% growth. This brings the company's revenue in the last twelve months to 33.20B, up 4.97% year-over-year. In the year 2025, GSK plc had annual revenue of 32.67B with 4.11% growth.
Revenue (ttm)
33.20B
Revenue Growth
+4.97%
P/S Ratio
2.33
Revenue / Employee
496.75K
Employees
66,841
Market Cap
77.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.25B |
| Haleon | 11.15B |
| Smith & Nephew | 4.58B |
| Hikma Pharmaceuticals | 2.49B |
| Convatec Group | 1.81B |
| Spire Healthcare Group | 1.58B |
| CVS Group | 692.80M |
| Genus | 672.00M |
GSK plc News
- 2 days ago - GSK Looks 14.7% Overvalued on GF Value⢠as Dividend Sustainability Remains Key - GuruFocus
- 2 days ago - GSK closer to relaunching Brexafemme, says Brookline - TheFly
- 2 days ago - Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals - Nasdaq
- 3 days ago - Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US - Reuters
- 3 days ago - GSK price target raised to 2,000 GBp from 1,950 GBp at Deutsche Bank - TheFly
- 3 days ago - GSK Strikes $100M AI Deal With Relation Therapeutics To Boost Early Pipeline - Nasdaq
- 3 days ago - GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal - Reuters
- 4 days ago - GSK Looks 19.3% Overvalued on GF Value⢠as Dividend Sustainability Faces Mixed Signals - GuruFocus